Heartflow (NASDAQ:HTFL) Sets New 1-Year Low After Insider Selling

Heartflow, Inc. (NASDAQ:HTFL) reached a new 52-week low during trading on Wednesday after an insider sold shares in the company. The stock traded as low as $25.36 and last traded at $26.42, with a volume of 575570 shares trading hands. The stock had previously closed at $27.30.

Specifically, CEO John C.M. Farquhar sold 22,562 shares of the firm’s stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $27.46, for a total value of $619,552.52. Following the transaction, the chief executive officer directly owned 591,656 shares of the company’s stock, valued at approximately $16,246,873.76. This trade represents a 3.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Julie A. Cullivan sold 8,000 shares of the business’s stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $27.32, for a total value of $218,560.00. Following the sale, the director directly owned 36,413 shares of the company’s stock, valued at $994,803.16. This represents a 18.01% decrease in their position. The disclosure for this sale is available in the SEC filing. In other news, major shareholder Bain Capital Life Sciences Inv sold 2,000,000 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $28.05, for a total value of $56,100,000.00. Following the transaction, the insider owned 10,448,158 shares of the company’s stock, valued at $293,070,831.90. This trade represents a 16.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Analysts Set New Price Targets

A number of equities research analysts have commented on HTFL shares. JPMorgan Chase & Co. raised their target price on shares of Heartflow from $36.00 to $40.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Stifel Nicolaus raised their price objective on shares of Heartflow from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Canaccord Genuity Group upped their target price on shares of Heartflow from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Wells Fargo & Company started coverage on Heartflow in a report on Wednesday, January 28th. They set an “overweight” rating and a $38.00 price target on the stock. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Heartflow in a research report on Monday, December 29th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Heartflow currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.50.

More Heartflow News

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Brokerages have raised price targets and added coverage (Wells Fargo started coverage with an “overweight”; JPMorgan, Stifel and Canaccord have lifted targets near $38–$40), which supports medium‑term upside expectations.
• Neutral Sentiment: Small institutional buys have shown modest inflows from several funds in recent quarters — a limited vote of confidence but not large enough to counter recent selling.
• Negative Sentiment: CEO John C.M. Farquhar sold 22,562 shares at about $27.46 (~$619.6k), trimming his stake — insider selling by the CEO can sap near‑term sentiment and supply. Insider Selling: CEO Form 4
• Negative Sentiment: Director Julie Cullivan sold 8,000 shares at about $27.32 (~$218.6k), cutting her holding ~18% — additional insider sales amplify negative optics. Director Sale
• Negative Sentiment: Short interest surged in late January to ~4.95M shares (up ~42% vs. mid‑January), representing roughly 5.8% of float and a ~5.9 days‑to‑cover — higher short positioning can amplify downside on negative news and increases selling pressure.
• Negative Sentiment: Reports of a large shareholder sell‑off (headline coverage cited a multi‑million dollar block sale) likely added supply and weighed on the stock. Major Shareholder Sale

Heartflow Stock Down 1.3%

The business has a 50 day moving average of $30.24. The company has a market capitalization of $2.30 billion and a P/E ratio of -14.89.

Institutional Trading of Heartflow

Several hedge funds and other institutional investors have recently bought and sold shares of HTFL. Wellington Management Group LLP purchased a new position in Heartflow during the third quarter worth $164,263,000. Baillie Gifford & Co. purchased a new position in shares of Heartflow during the 3rd quarter worth about $101,182,000. Schusterman Interests LLC purchased a new stake in Heartflow in the 3rd quarter worth about $65,274,000. Vanguard Group Inc. lifted its stake in Heartflow by 8.8% in the fourth quarter. Vanguard Group Inc. now owns 1,580,313 shares of the company’s stock worth $46,066,000 after purchasing an additional 128,400 shares during the last quarter. Finally, Capital International Investors purchased a new position in shares of Heartflow during the third quarter valued at approximately $43,671,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.